OKYO Pharma Ltd (OKYO) Insider Trading & SEC Filings
SEC Form 4 insider transactions, executive purchases and 10% owner activity.
About OKYO Pharma Ltd (OKYO)
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
90-Day SEC Filing Activity
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 6 | 71,863 | $103.4K |
| Grant or award | 12 | 450,863 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Recent OKYO Insider Transactions (Form 4)
18| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John P. Brancaccio - Director | Open-market purchase | COMMON STOCK | 5,000 | $1 | $7.4K | |
| Robert John Dempsey - Officer | Open-market purchase | COMMON STOCK | 15,000 | $2 | $23.1K | |
| Gary S. Jacob - Officer | Open-market purchase | COMMON STOCK | 3,500 | $1 | $4.9K | |
| Gabriele M. Cerrone - Director | Open-market purchase | COMMON STOCK | 25,000 | $1 | $35.0K | |
 Flavio Mantelli - Officer | Open-market purchase | COMMON STOCK | 20,000 | $1 | $28.0K | |
| Rajkumar V. Patil - Officer | Open-market purchase | COMMON STOCK | 3,363 | $1 | $5.0K | |
| Rajkumar V. Patil - Officer | Grant or award | COMMON STOCK | 3,363 | $1 | $5.0K | |
| Robert John Dempsey - Officer | Grant or award | COMMON STOCK | 15,000 | $2 | $23.1K | |
| Gabriele M. Cerrone - Director | Grant or award | COMMON STOCK | 22,500 | $1 | $32.6K | |
| Gary S. Jacob - Officer | Grant or award | COMMON STOCK | 3,500 | $1 | $4.9K | |
| John P. Brancaccio - Director | Grant or award | COMMON STOCK | 5,000 | $1 | $7.4K | |
| Flavio Mantelli - Officer | Grant or award | COMMON STOCK | 20,000 | $1 | $28.0K | |
| Gabriele M. Cerrone - Director | Grant or award | COMMON STOCK | 25,000 | $1 | $35.0K | |
 Bernard Denoyer - Director | Grant or award | Option | 3,500 | $2 | $6.5K | |
| John P. Brancaccio - Director | Grant or award | Option | 6,500 | $2 | $12.0K | |
| Willy Jules Simon - Director | Grant or award | Option | 6,500 | $2 | $12.0K | |
| Keeren Rameshchandra Shah - Officer | Grant or award | Option | 40,000 | $2 | $74.0K | |
| Gabriele M. Cerrone - Director | Grant or award | COMMON STOCK | 300,000 | $2 | $516.0K |
Most-Active OKYO Insiders - Last 90 Days
9Form 4 Transaction Code Reference
- P - Open-market purchase by the insider
- S - Open-market sale by the insider
- A - Grant, award, or other acquisition from the issuer
- M - Exercise or conversion of derivative security (e.g. options)
- F - Payment of exercise price or tax liability via share withholding
- G - Bona-fide gift of securities
- D - Disposition to the issuer (e.g. share buyback participation)
- J - Other acquisition or disposition
- X - Exercise of in-the-money or at-the-money derivative security
- C - Conversion of derivative security
- V - Transaction voluntarily reported earlier than required
OKYO Insider Trading - FAQ
What is the latest insider trade for OKYO?
OKYO Pharma Ltd (OKYO) had 18 insider filings in the last 90 days, with the most recent on 2026-08-07. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying OKYO stock?
6 insider purchases of OKYO were filed in the last 90 days, totaling $103K.
How many insiders are selling OKYO stock?
0 insider sales of OKYO were filed in the last 90 days.
Where can I see OKYO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks OKYO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Companies with Insider Activity
Recent Insider Filings
18Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
- - John P. Brancaccio view on EDGAR
- - Robert John Dempsey view on EDGAR
- - Gary S. Jacob view on EDGAR
- - Gabriele M. Cerrone view on EDGAR
- - Flavio Mantelli view on EDGAR
- - Rajkumar V. Patil view on EDGAR
- - Rajkumar V. Patil view on EDGAR
- - Robert John Dempsey view on EDGAR
- - Gabriele M. Cerrone view on EDGAR
- - Gary S. Jacob view on EDGAR
Learn More
- What is SEC Form 4?
- The filing insiders must submit within two business days of a trade, and how to read its transaction codes.
- Insider trading guides
- How to tell a conviction purchase from a scheduled sale, and which signals historically carry information.
- Every recent Form 4
- The full market-wide feed, updated as filings arrive from SEC EDGAR.
- Browse all companies
- Search by ticker or name for any company with insider activity on record.
- Notable insider profiles
- Track records for the executives and directors who file most often.
- Insider activity by sector
- Where buying and selling is concentrated across the eleven GICS sectors.
- Today's daily plan
- The day's Form 4 purchases, scored and ranked with entry and exit levels.
- MCP for AI assistants
- Query this data directly from Claude, ChatGPT or Cursor.
Track OKYO insider activity as it files
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.